MedTrace Logo

Non-Invasive ctDNA Methylation Detection for Lung Nodule Patients

NCT03685669 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2019-01-23

No results posted yet for this study

Summary

Low-dose computed tomography (LDCT) is recommended for early-stage lung cancer screening. However, it is often difficult to determine indolent lesions from more aggressive tumors without an invasive intervention or prolonged follow-up period. Thus, the main purpose of this study is to develop a non-invasive method to detect lung-cancer specific circulating tumor DNA (ctDNA) in blood, which can greatly improve the specificity of lung cancer early screening.

Conditions

  • Lung Nodule

Sponsors & Collaborators

  • Singlera Genomics Inc.

    collaborator INDUSTRY

  • Shanghai Chest Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2019-06-30
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03685669 on ClinicalTrials.gov